183,243 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Purchased by Silverarc Capital Management LLC

Silverarc Capital Management LLC bought a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 183,243 shares of the company's stock, valued at approximately $7,920,000. Scholar Rock accounts for approximately 1.7% of Silverarc Capital Management LLC's portfolio, making the stock its 19th biggest position. Silverarc Capital Management LLC owned approximately 0.20% of Scholar Rock at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of SRRK. FMR LLC raised its holdings in shares of Scholar Rock by 33.7% in the fourth quarter. FMR LLC now owns 13,635,261 shares of the company's stock valued at $589,316,000 after buying an additional 3,439,215 shares during the last quarter. Marshall Wace LLP lifted its position in Scholar Rock by 1,283.7% during the 4th quarter. Marshall Wace LLP now owns 2,945,408 shares of the company's stock worth $127,301,000 after acquiring an additional 2,732,546 shares during the period. Norges Bank purchased a new position in shares of Scholar Rock in the 4th quarter valued at approximately $86,043,000. Wellington Management Group LLP increased its holdings in shares of Scholar Rock by 763.8% in the fourth quarter. Wellington Management Group LLP now owns 1,725,622 shares of the company's stock valued at $74,581,000 after purchasing an additional 1,525,845 shares during the period. Finally, Loomis Sayles & Co. L P purchased a new stake in shares of Scholar Rock during the fourth quarter worth approximately $33,567,000. Hedge funds and other institutional investors own 91.08% of the company's stock.

Scholar Rock Price Performance

Scholar Rock stock traded down $1.57 during midday trading on Friday, reaching $32.81. The company's stock had a trading volume of 694,304 shares, compared to its average volume of 1,243,667. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The firm has a market capitalization of $3.11 billion, a PE ratio of -13.96 and a beta of 0.56. The stock's 50 day simple moving average is $32.77 and its 200 day simple moving average is $35.66.

Insider Buying and Selling

In other Scholar Rock news, CFO Edward H. Myles sold 142,292 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $35.62, for a total value of $5,068,441.04. Following the sale, the chief financial officer now owns 111,345 shares of the company's stock, valued at approximately $3,966,108.90. This represents a 56.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mo Qatanani sold 68,510 shares of Scholar Rock stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total value of $2,562,274.00. Following the transaction, the insider now directly owns 111,084 shares of the company's stock, valued at $4,154,541.60. This trade represents a 38.15 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 250,231 shares of company stock valued at $9,056,086. Corporate insiders own 13.30% of the company's stock.

Analysts Set New Price Targets

Separately, Wedbush reissued an "outperform" rating and issued a $50.00 price objective on shares of Scholar Rock in a research note on Tuesday, March 25th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $42.67.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.